Safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: A phase Ib study.

Saad A Arain,Sonia Christian,Pritesh R. Patel,Karen Sweiss,Brian Parkin,Gregory S. Calip,John G. Quigley

Safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: A phase Ib study.

2020

Saad A Arain
Sonia Christian
Pritesh R. Patel
Karen Sweiss
Brian Parkin
Gregory S. Calip
John G. Quigley

TPS7566Background: AML is predominantly a disease of the elderly, yet outcomes remain dismal, especially for relapsed/refractory (R/R) AML patients (pts). Gemtuzumab Ozogamicin (GO) is a monoclonal...

Keywords:

Oncology
Internal medicine
CD33
Venetoclax
Myeloid leukemia
Gemtuzumab ozogamicin
Refractory
Medicine
Pathology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations